Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ghaly G, Kamel M, Nasar A, et al. Locally advanced esophageal cancer: what becomes of 5-year survivors? J Thorac Cardiovasc Surg. 2016;151(3):726–732. doi:10.1016/j.jtcvs.2015.10.096
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: esophageal and stomach cancer. Avialable from: https://seer.cancer.gov/statfacts/html/esoph.html. Accessed December 30, 2022.
   Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148.
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, Phase 3 trial. BMJ. 2022;377:e068714. doi:10.1136/bmj-2021-068714
   PubMedGoogle Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386(5):449–462. doi:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.8
   PubMed Web of Science ®Google Scholar
• Stone E, Vinod SK. Oligometastatic disease in NSCLC - not just wishful thinking? J Thorac Oncol. 2019;14(12):2042–2045. doi:10.1016/j.jtho.2019.10.008
   Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi:10.6004/jnccn.2021.0013
   PubMed Web of Science ®Google Scholar
• Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019;122:109–114. doi:10.1016/j.ejca.2019.09.012
   PubMed Web of Science ®Google Scholar
• Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14(12):2109–2119. doi:10.1016/j.jtho.2019.07.025
   Web of Science ®Google Scholar
• Xu Y, Dong B, Zhu W, et al. A phase iii multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Clin Cancer Res. 2022;28(9):1792–1799. doi:10.1158/1078-0432.CCR-21-3843
   Web of Science ®Google Scholar
• Borg D, Sundberg J, Brun E, et al. Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the Phase II PALAESTRA trial. Acta Oncol. 2020;59(2):212–218. doi:10.1080/0284186X.2019.1670861
   PubMed Web of Science ®Google Scholar
• Li J, Wen Y, Xiang Z, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol. 2021;154:201–206. doi:10.1016/j.radonc.2020.09.042
   Web of Science ®Google Scholar
• Shi Z, Zhu X, Ke S, et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiother Oncol. 2021;164:236–244. doi:10.1016/j.radonc.2021.09.033
   Web of Science ®Google Scholar
• Liu Q, Zhu Z, Chen Y, et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(3):707–715. doi:10.1016/j.ijrobp.2020.05.003
   PubMed Web of Science ®Google Scholar
• Li B, Wang R, Zhang T, et al. Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. Sci Rep. 2020;10(1):11259. doi:10.1038/s41598-020-68160-6
   Web of Science ®Google Scholar
• Dovedi SJ, Cheadle EJ, Popple AL, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514–5526. doi:10.1158/1078-0432.CCR-16-1673
   PubMed Web of Science ®Google Scholar
• Gong X, Li X, Jiang T, et al. Combined radiotherapy and Anti-PD-L1 Antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1085–1097. doi:10.1016/j.jtho.2017.04.014
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313
   PubMed Web of Science ®Google Scholar
• Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology. 2021;10(1):1971418. doi:10.1080/2162402X.2021.1971418
   PubMed Web of Science ®Google Scholar
• Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–166. doi:10.1016/j.radonc.2020.04.003
   PubMed Web of Science ®Google Scholar
• Kroese TE, Christ SM, van Rossum PSN, et al. Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study. Radiother Oncol. 2022;173:269–276. doi:10.1016/j.radonc.2022.06.012
   Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020;8(2):e001001. doi:10.1136/jitc-2020-001001
   PubMed Web of Science ®Google Scholar
• Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional Phase I/II trials. Int J Radiat Oncol Biol Phys. 2018;101(5):1141–1148. doi:10.1016/j.ijrobp.2018.04.054
   Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi:10.1016/S0140-6736(18)32487-5
   PubMed Web of Science ®Google Scholar
• Zhang W, Yan C, Gao X, et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 2021;26(7):e1110–e1124. doi:10.1002/onco.13797
   PubMed Web of Science ®Google Scholar